Last 116.00 GBp
Change Today 0.00 / 0.00%
Volume 13.1K
SUMM On Other Exchanges
As of 11:30 AM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

summit corporation plc (SUMM) Snapshot

116.00 GBp
Previous Close
116.00 GBp
Day High
116.00 GBp
Day Low
116.00 GBp
52 Week High
01/20/14 - 267.50 GBp
52 Week Low
07/22/14 - 101.25 GBp
Market Cap
Average Volume 10 Days
-0.33 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

summit corporation plc (SUMM) Related Businessweek News

No Related Businessweek News Found

summit corporation plc (SUMM) Details

Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.

20 Employees
Last Reported Date: 06/4/14
Founded in 2003

summit corporation plc (SUMM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 180.0K GBP
Compensation as of Fiscal Year 2014.

summit corporation plc (SUMM) Key Developments

Summit Announces Resignation of Jim Mellon as Non-Executive Director

Summit announced that the board has accepted the resignation of Jim Mellon as a non-executive director of the company, effective immediately. Mellon has resigned due to the pressure of his other work responsibilities and the challenge of visits to the UK.

Summit Corporation Appoints Valerie Andrews as Non-Executive Director

Summit Corporation has appointed Ms. Valerie Andrews as Non-Executive Director. The effective date is September 19, 2014. Ms. Valerie Andrews has extensive skills in business and legal matters related to the healthcare industry having held executive and non-executive roles within publically listed biotechnology companies, major hospitals and in legal practice. Ms. Andrews has a range of expertise across a number of areas including strategic transactions, corporate governance, risk management and compliance. Ms. Andrews served as the General Counsel for Vertex Pharmaceuticals Inc. until May 2014.

Summit Corporation plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended July 31, 2014

Summit Corporation plc announced unaudited consolidated earnings results for the six months ended July 31, 2014. For the period, the company reported revenue of £574,000 against £504,000 a year ago. Operating loss was £6,397,000 against £2,387,000 a year ago. Loss before tax was £6,372,000 against £2,381,000 a year ago. Loss for the period attributable to owners of the parent was £5,906,000 against £2,139,000 a year ago. Basic and diluted loss per ordinary share was 15.51 pence against 11.93 pence, a year ago. Net cash used in operations was £5,299,000 against £1,863,000 a year ago. Purchase of property, plant and equipment was £16,000 against £22,000 a year ago Cash position as at July 31, 2014 was £17.4 million against £2.0 million, as of January 31, 2014. The enhanced cash position is predominantly due to the completion in March of a financing that raised £22.0 million through the issue of new ordinary shares. These funds raised primarily from existing shareholders and specialist healthcare investors in the US and Europe, will support the execution of the clinical development plans towards establishing proof of concept in the DMD and CDI programmes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUMM:LN 116.00 GBp 0.00

SUMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUMM.
View Industry Companies

Industry Analysis


Industry Average

Valuation SUMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.5x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMMIT CORPORATION PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at